HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Effect of eszopiclone on sleep, fatigue, and pain in patients with mucositis associated with hematologic malignancies.

AbstractPURPOSE:
Patients with malignancy sometimes develop painful mucositis and require patient-controlled analgesia (PCA) to treat their pain. Pain disrupts sleep and there is some evidence that analgesic medications also disrupt sleep. This study examined whether treatment with the sedative hypnotic eszopiclone could improve self-reports of sleep, fatigue, and pain as well as decrease opioid self-administered via PCA.
METHODS:
Inpatients who developed mucositis severe enough to require PCA treatment were randomized double-blind to a 2-day trial on eszopiclone or placebo-administered at bedtime. Patients completed questionnaires which assessed sleep, pain, and fatigue. PCA medication was calculated in terms of morphine equivalents. Data were analyzed with unpaired t tests and repeated measures analysis of variance.
RESULTS:
Twenty-two patients were randomized to placebo and 23 to eszopiclone. Groups were comparable in age and treatment characteristics. Mean pain scores were lower in the eszopiclone group at all time points (morning p = 0.01, afternoon p = 0.04, evening p = 0.04). The eszopiclone group reported increased sleep time (p < 0.05), fewer nighttime awakenings (p < 0.001), better self-reported sleep quality (p = 0.01), and depth (p = 0.04). There were no significant differences between eszopiclone and placebo in terms of self-reports of fatigue or opioid usage.
CONCLUSION:
Sedative hypnotic agents improve sleep and analgesia even in the setting of considerable pain and discomfort.
AuthorsJoel E Dimsdale, Edward D Ball, Ewa Carrier, Mark Wallace, Peter Holman, Carolyn Mulroney, Farah Shaikh, Loki Natarajan
JournalSupportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer (Support Care Cancer) Vol. 19 Issue 12 Pg. 2015-20 (Dec 2011) ISSN: 1433-7339 [Electronic] Germany
PMID21116652 (Publication Type: Journal Article, Randomized Controlled Trial, Research Support, Non-U.S. Gov't)
Chemical References
  • Azabicyclo Compounds
  • Hypnotics and Sedatives
  • Piperazines
  • Eszopiclone
Topics
  • Adult
  • Azabicyclo Compounds (administration & dosage, therapeutic use)
  • Eszopiclone
  • Fatigue (chemically induced)
  • Hematologic Neoplasms (complications)
  • Humans
  • Hypnotics and Sedatives (administration & dosage, therapeutic use)
  • Middle Aged
  • Mucositis (complications, etiology, physiopathology)
  • Pain (drug therapy, etiology)
  • Piperazines (administration & dosage, therapeutic use)
  • Sleep (drug effects)
  • Surveys and Questionnaires

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: